+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Kellogg Family Early-Career PatientOriented Diabetes Research Award

Breakthrough T1D

Brief Description Designed to provide crucial support to investigators who plan to pursue a career in diabetesrelated clinical investigation. Awards are made in the later stages of training and include the ability for recipients to transition to independent faculty or research appointments

Institutional Eligibility Domestic & foreign non-profit organizations; public & private universities, colleges, hospitals, laboratories; units of state & local governments; eligible agencies of the federal government

Applicant Eligibility In most cases, applicant will have an MD, MD-PhD, DO, or PsyD, hold an appointment or joint appointment in a subspecialty of clinical medicine, and conduct human clinical research

Terms 200,000 USD maximum/year for up to 5 years, including up to 10% for indirect costs and generally not renewable after 5 years.

AI Based Application Success Predictor

1. Strong alignment with Breakthrough T1D strategic priorities (highest predictor)

This is the single most important predictor.

Breakthrough T1D prioritizes research in areas such as:

Disease-modifying therapies
Prevention of T1D
Beta-cell replacement and regeneration
Immune tolerance and immunotherapy
Screening and early detection
Diabetes technology (CGM, automated insulin delivery)
Complication prevention
Precision medicine approaches
Cell therapies

Projects that clearly fit current strategic funding priorities are substantially more competitive than investigator-driven projects with only indirect relevance.

2. Clear path toward improving outcomes for people with T1D (very high predictor)

Breakthrough T1D is highly mission-driven.

Competitive proposals typically demonstrate potential to:

Delay or prevent T1D onset
Preserve beta-cell function
Improve glycemic control
Reduce disease burden
Improve quality of life
Prevent complications
Move toward a functional cure

Reviewers often place strong emphasis on translational impact and patient benefit.

3. Translational potential and milestone-driven development (very high predictor)

Compared with many traditional research funders, Breakthrough T1D places exceptional emphasis on translation.

Successful applications often include:

Clearly defined milestones
Product-development pathways
Regulatory considerations
Commercialization strategies when relevant
Go/no-go decision points

Projects that can advance toward clinical testing or implementation frequently receive favorable consideration.

4. Strong scientific rationale and mechanistic foundation

Even highly translational proposals must demonstrate:

Strong biological rationale
Sound preliminary evidence
Mechanistic understanding
Robust study design
Appropriate statistical planning

Breakthrough T1D supports innovation, but projects must be scientifically credible and well supported.

5. Investigative team expertise and multidisciplinary collaboration

Many funded projects involve collaborations among:

Immunologists
Endocrinologists
Beta-cell biologists
Bioengineers
Computational scientists
Clinical trialists
Industry partners

Strong multidisciplinary teams are often viewed favorably, especially for complex translational projects.

6. Preliminary data and feasibility

Although some exploratory programs support early-stage ideas, most competitive applications include:

Preliminary data
Proof-of-concept evidence
Feasibility studies
Pilot results

Reviewers want confidence that proposed milestones can realistically be achieved.

7. Potential to attract follow-on investment or larger funding

Breakthrough T1D frequently acts as a catalyst for:

NIH funding
Industry partnerships
Venture investment
Advanced translational development

Projects likely to generate future funding opportunities often receive positive consideration.

8. Patient-centered relevance and community impact

A distinctive feature of Breakthrough T1D is its close engagement with the T1D community.

Strong projects often consider:

Patient priorities
Real-world usability
Treatment burden
Accessibility
Health equity
Long-term quality-of-life outcomes

Research that addresses meaningful patient needs tends to resonate strongly with reviewers.

9. Innovation and potential for transformative impact

Breakthrough T1D is willing to support ambitious science when the potential payoff is substantial.

Competitive projects frequently involve:

Novel immunotherapies
Advanced cell therapies
Gene-editing approaches
AI-driven diabetes management
New biomarkers
Transformative disease-modifying strategies

Innovation alone is not sufficient, but highly innovative projects with strong feasibility are particularly attractive.

Specialties

Endocrinology and Diabetes

Eligibility Requirements

Applicant

The Early Career Patient-Oriented Diabetes Research Award is intended for clinical researchers at a relatively early stage of their independent career. Clinical researchers who have received their first faculty-level appointment less than 5 years before the submission date are eligible to apply for this award. Applicants must have an MD, MD-PhD, DO, or PsyD, hold an appointment or joint appointment in a subspecialty of clinical medicine in a clinical department, and conduct human clinical research. In exceptional circumstances, non-MD candidates will be considered if their work is likely to contribute significantly to a clinical outcome. For the purposes of this award, clinical research is defined as research conducted with human subjects for which the investigator directly interacts with the subjects.

Breakthrough T1D is sensitive to personal and COVID-related matters that impact career trajectories. Applicants who have taken leave from their career (e.g. parenting of a child, childbirth, long-term care of a parent/spouse/child/dependent, personal health issues) or experienced a delay due to COVID shutdowns that puts them outside of the eligibility time frame for the award mechanism should reach out to Breakthrough T1D staff ahead of their application submission. Breakthrough T1D aims to be flexible and adjust these time frames if necessary and as appropriate.

Sponsor Details

Sponsor Institute/Organizations: Breakthrough T1D

Sponsor Type: Corporate/Non-Profit

Address: 200 Vesey Street, 28th Floor, New York, NY 10281

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity